

Chelsea and Westminster Hospital NHS Foundation Trust Medicines Committee

Summary Notes from the Meeting held on the 13th of September 2010

2. Minutes and Summary Notes from last meeting

The Minutes and Summary notes were approved with a minor amendment.

3. Matters Arising

All of the actions were completed with the exception of reformatting of the electrolyte guidelines, this is in progress.

4. New Medicines Applications

Formulary Application

Capsaicin 8% patch. Indication: Licensed. **Decision:** Approved **Tariff:** Included

Restricted for 3rd line treatment of peripheral neuropathic pain, e.g. HIV-related neuropathy, post-herpetic neuralgia, complex regional pain syndrome (CRPS), cancer pain and post-surgical neuropathic pain.

Individual Funding Requests - Nil

Rituximab for Subacute Cutaneous Lupus Erythematosus (ex-panel) Indication: Unlicensed **Decision:** Approved
Tariff: Excluded (Long form)

5. Medicines Policy Updates

The committee approved six updates to the medicines policy

Section 7 – Unlicensed Medicines and *Section 22 – Non-medical Prescribing* have been updated to reflect changes in the approval process for Unlicensed Medicinal Products (UMPS), changes to the law allowing non-medical prescribers to prescribe UMPS outside a clinical management plan, guidance from the MHRA on mixing of medicines by non-medical prescribers and increasing FP10HP prescribing off-site.

The *Appendix- Controlled Drug Governance Arrangements* has been reviewed as it has reached its expiry date with minor changes. It was approved pending changes to be made including replacing references to the Healthcare Commission with the Care Quality Commission, updating details of the Accountable Officer for NHS K&C and LIN meetings.

Medicines Management Programme of Development – updated for 2010

Formulary Application Form – updated to reflect divisional changes

Procedure for the Supply of Discharge Medicines by Nurses/Midwives from Ward Cupboards- now incorporates the use of Pharmacy Only (P) or General sales List (GSL) manufacturer's packs without over labels, where appropriate.

6. NELM Formulary

The C&W web based formulary; the first to be published on NELM was demonstrated.

Link: <http://www.nelm.nhs.uk/en/Formularies/Trusts/Chelsea-Westminster-Formulary/>

Formulary Items for deletion

A list of discontinued formulary items for deletion was approved.

7. Monthly Trust progress against specific prescribing related CQUIN targets: Proton Pump Inhibitors and Antibiotics

The committee noted the current monthly (August) PPI CQUIN compliance is at 71% (target minimum = 80% and stretch = 95%). Currently the Trust is not meeting the CQUIN stretch target. Current monthly (August) **antibiotic CQUIN** compliance is at 95% (target minimum = 85% and stretch = 95%). Currently the Trust is meeting the CQUIN minimum and stretch target. An action plan to improve PPI compliance is in progress.

8. NICE Guidance

The committee noted the following NICE Guidance:

TA191 Gastric cancer (advanced) - capecitabine

TA192 Lung cancer (non-small-cell, first line) - gefitinib

TA193 Leukaemia (chronic lymphocytic, relapsed) - rituximab

TA194 Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal)

TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor

TA196 Gastrointestinal stromal tumours - imatinib (adjuvant) (not applicable to C&W)

TA197 Atrial fibrillation - dronedarone

Chelsea and Westminster Hospital NHS Foundation Trust Medicines Committee

TA198 Rheumatoid arthritis - tocilizumab

TA199 Psoriatic arthritis - etanercept, infliximab and adalimumab

Formulary status for capecitabine, gefitinib, rituximab, tocilizumab, etanercept, infliximab and adalimumab would be updated in line with NICE guidance and the chairman would request a formulary application for dronedarone.

9. NPSA

The committee noted the following NPSA Alerts. Trust Action plans and gap analyses were in progress.

- Prevention of over infusion of intravenous fluid and medicines in neonates
- Reducing treatment dose errors with low molecular weight heparins

10. IVIG Update

The committee approved IVIG requests and supplies for July (18 issues) and August 2010 (14 issues).

11. Items for noting

The committee noted the following items:

a) Audit: Medicines Policy Audit

The report was noted. A full discussion was deferred to the October meeting due to time constraints.

b) Trust Quarterly CD report and Accountable Officer Quarter 1 Occurrence Report

This was noted. 3 occurrences that had occurred were investigated fully and reported to the Accountable officer.

c) Trust Policy for the Safe Prescribing, Handling and Administration of Cytotoxic Chemotherapy

Noted. This would be published on the Trust Intranet.

d) Updated Trust Register of Non-medical Prescribers

Noted. This would be published on the Trust Intranet.

e) Short forms for Adalimumab and Infliximab in Crohn's and Gefitinib in NSLC

Noted. These would be disseminated to the relevant clinicians and published on the Trust Intranet.

12. Papers to go to the Trust Executive Quality Committee

The following papers should be sent to the Trust Executive Team – Quality Committee:

- Medicines Committee Summary Notes July 2010
- Trust Quarterly CD report & Accountable Officer Quarter 1 Occurrence Report
- Medicines Policy Audit

Date of the next meeting

Monday 11th of October 2010, 08.00 to 09.00, Board Room

Closing date for papers: Friday September 17, 2010